ArticleMolecular biology reports2026
Epigallocatechin gallate enhances panobinostat-induced cytotoxicity through HDAC modulation in colorectal cancer cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeColorectal cancer (CRC) is a major cause of cancer-related death due to recurrence and therapeutic resistance. This study evaluates whether combining panobinostat, a histone deacetylase (HDAC) inhibitor, with epigallocatechin gallate (EGCG), a green tea-derived polyphenol, enhances anti-tumor activity through modulation of HDAC expression in CRC cell lines.
methodsCytotoxicity and migration were assessed in HCT-116 and HT-29 cells. Combination studies were performed using sub-cytotoxic concentrations (less than IC₂₅), and HDAC1, HDAC2, and HDAC4 expression levels were quantified by qPCR.
resultsThe combination of panobinostat and EGCG produced synergistic cytotoxic effects at low, sub-cytotoxic doses. Compared with single-agent treatment, co-treatment enhanced the cytotoxic activity of panobinostat. In HT-29 cells, EGCG inhibited migration, while 5 nM panobinostat alone showed minimal effect. Higher panobinostat doses (10 nM) and certain combination treatments significantly reduced migration. In HCT-116 cells, migration responses were limited, although selected combinations produced significant inhibition at 72 h. Mechanistically, EGCG downregulated HDAC1 in HT-29 cells and HDAC2 and HDAC4 in HCT-116 cells. In contrast, panobinostat and combination treatments upregulated HDAC expression, suggesting compensatory transcriptional feedback in response to HDAC inhibition.
conclusionPanobinostat combined with EGCG exerts synergistic cytotoxic effects in CRC, accompanied by time-and cell line-specific inhibition of cell migration and modulation of HDAC expression.
Indexed as
Identifiers
42455377What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.